•  
  •  
 

Central Asian Journal of Medicine

Abstract

The emergence of new direct-acting antivirals C, scientists and doctors consider a revolution in hepatology and predict an early victory over hepatitis C. After all, now the treatment course has become much more successful and safe than before. The criterion for the success of treatment is the achievement of SVR - a sustained virologic response, that is, the failure of the hepatitis C virus. But how was it before? What did the therapy lack for success?

First Page

59

Last Page

70

References

1. Alter H.J., Holland P.V., Morrow A.G. et al. Clinical and serological analysis of transfusion-associated hepatitis // Lancet. – 1975. – Vol. 2 (7940). – P. 838-841. 2. Behnam M.A.M., Nitsche Ch., Boldescu V., Klein Ch.D. The medicinal chemistry of dengue virus // J. Med. Chem. – 2016. – Vol. 59, №12. – P. 5622. 3. Di Bisceglie A.M., Shindo M., Fong T.L. et al. A pilot study of ribavirin therapy for chronic hepatitis C // Hepatology. – 1992. – Vol. 16, №3. – P. 649-654. 4. Dienstag J.L. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features // Gastroenterology. – 1983. – Vol. 85. – P. 439-462. 5. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. – 2009. – Vol. 461. – P. 399-401. 6. Ghany M.G., Nelson D.R., Strader D.B. et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases // Hepatology. – 2011. – Vol. 54. – P. 1433-1444. 7. Guedj J., Dahari H., Uprichard S.L., Perelson AS. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate // Exp. Rev. Gastroenterol. Hepatol. – 2013. – Vol. 7. – P. 397-399. 8. Hoofnagle J.H. Chronic hepatitis: the role of corticosteroids // W. Szmuness, H.J. Alter, J.E. Maynard; editors. Viral hepatitis: the 1981 International Symposium. – Philadelphia, Pennsylvania: Franklin Institute Press, 1981. – P. 573-583. 9. Hoofnagle J.H., Mullen K.D., Jones D.B. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report // New Engl. J. Med. – 1986. – Vol. 315. – P. 1575-1578. 10. Krugman S., Giles J.P. Viral hepatitis. New light on an old disease // J.A.M.A. – 1970. – Vol. 212. – P. 1019-1029. 11. Maccari S., Bassi C., Giovanni A.G., Plancher A.C. A Case of Arthropathy and Hypothyroidism during Recombinant Alpha-Interferon Therapy // Clin. Rheum. Dec. – 1991. – Vol. 10, Issue 4. – P. 452-454. 12. McHutchison J.G., Gordon S.C., Schiff E.R. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C // New Engl. J. Med. – 1998. – Vol. 339. – P. 1485-1492. 13. Pappas S.C., Hoofnagle J.H., Young N. et al. Treatment of chronic non-A, non-B hepatitis with acyclovir: pilot study // J. Med. Virol. – 1985. – Vol. 15. – P. 1-9. 14. Pawlotsky J.M. NS5A inhibitors in the treatment of hepatitis C // J. Hepatol. – 2013. – Vol. 59. – P. 375-382. 15. Pawlotsky J.M. The science of direct-acting antiviral and host-targeted agent therapy // Antivir. Ther. – 2012. – Vol. 17. – P. 1109-1117. 16. Simmonds P. The origin of hepatitis C virus // Curr. Top. Microbiol. Immunol. – 2013. – Vol. 369. – P. 1-15.

Share

COinS